Impact of small body weight on Tenofovir-Associated renal dysfunction in HIV-infected patients: A retrospective cohort study of Japanese patients

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Nishijima, Takeshi ^a,c   Komatsu, Hirokazu ^b   Gatanaga, Hiroyuki ^a,c   Aoki, Takahiro ^a   Watanabe, Koji ^a,c   Kinai, Ei ^a   Honda, Haruhito ^a   Tanuma, Junko ^a   Yazaki, Hirohisa ^a   Tsukada, Kunihisa ^a   Honda, Miwako ^a   Teruya, Katsuji ^a   Kikuchi, Yoshimi ^a   Oka, Shinichi ^a,c  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CREATININE; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ADOLESCENT; ADULT; AGING; ARTICLE; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CIGARETTE SMOKING; COHORT ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; JAPANESE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VIRUS LOAD; ASIAN; DRUG EFFECT; KIDNEY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY;

HEPATITIS C VIRUS;

ADENINE; ADULT; ANTI-HIV AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES;

EID: 79960725563     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022661     Document Type: Article

References (36)

1. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260.
2. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201.
3. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, et al. (2005) Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 20: 743-746.
4. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, et al. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21: 1273-1281.
5. Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, et al. (2008) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 47: 74-78.
6. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, et al. (2010) Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 55: 49-57.
7. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, et al. (2002) Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 40: 1331-1333.
8. Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K, (2003) Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 37: e41-43.
9. Rollot F, Nazal EM, Chauvelot-Moachon L, Kelaidi C, Daniel N, et al. (2003) Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 37: e174-176.
10. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, et al. (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35: 269-273.
11. Kinai E, Hanabusa H, (2009) Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses 25: 387-394.
12. Winston A, Amin J, Mallon P, Marriott D, Carr A, et al. (2006) Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 7: 105-111.
13. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, et al. (2008) The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 22: 2155-2163.
14. Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, et al. (2007) Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12: 1165-1173.
15. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505.
16. Gayet-Ageron A, Ananworanich J, Jupimai T, Chetchotisakd P, Prasithsirikul W, et al. (2007) No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother 59: 1034-1037.
17. Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S, (2010) Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res 8: 504-509.
18. Reid A, Stohr W, Walker AS, Williams IG, Kityo C, et al. (2008) Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 46: 1271-1281.
19. Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, et al. (2006) Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 22: 744-748.
20. Goicoechea M, Liu S, Best B, Sun S, Jain S, et al. (2008) Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197: 102-108.
21. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, et al. (2009) Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48: e108-116.
22. Bash LD, Coresh J, Kottgen A, Parekh RS, Fulop T, et al. (2009) Defining incident chronic kidney disease in the research setting: The ARIC Study. Am J Epidemiol 170: 414-424.
23. Chue CD, Edwards NC, Davis LJ, Steeds RP, Townend JN, et al. (2011) Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrol Dial Transplant doi:10.1093/ndt/gfq78.
24. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254.
25. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, et al. (2005) Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40: 1559-1585.
26. Lomaestro BM, (2000) Fluoroquinolone-induced renal failure. Drug Saf 22: 479-485.
27. Wever K, van Agtmael MA, Carr A, (2010) Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 55: 78-81.
28. Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, et al. (2004) Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 39: 1199-1206.
29. Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, et al. (2008) Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 3: 348-354.
30. Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, et al. (2005) Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 6: 284-290.
31. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, et al. (2010) Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 53: 62-69.
32. Post FA, Holt SG, (2009) Recent developments in HIV and the kidney. Curr Opin Infect Dis 22: 43-48.
33. Jullien V, Treluyer JM, Rey E, Jaffray P, Krivine A, et al. (2005) Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother 49: 3361-3366.
34. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, et al. (2008) Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52: 3144-3160.
35. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, et al. (2009) Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 89: 513-519.
36. Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, et al. (2008) Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 52: 631-637.